drugset / Trial / NCT00887328

Summary

The primary hypothesis being tested in this trial is that ischaemic stroke patients selected with significant penumbral mismatch (measured by MRI criteria) at 3 - 9 hours post onset of stroke will have improved clinical outcomes when given intravenous tissue plasminogen activator (tPA) compared to placebo.

Timeline

Start
2010-06
Primary completion
2018-08-27
Completion
2018-08-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 0.9 mg/kg Intravenous

Indications